Drugs / hMSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04780685 | Mar 2021 → Sep 2022 | COVID-19 | Stemedica Cell Technologies, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hMSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04780685 ↗ |
| Modality | Cell therapy | “Intravenous Allogeneic Mesenchymal Stem Cells” NCT04780685 ↗ |
| Route | Intravenous | “hMSCs will be given via IV administration.” NCT04780685 ↗ |